Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

46.15 UNCHANGED
Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Exelixis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Exelixis Announces Detailed Phase 1b Results from Cohort 6 of COSMIC-021 Trial in Patients with Metastatic Castration-Resistant Prostate Cancer Presented at ESMO 2021
From Exelixis, Inc.
Via Business Wire
Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
From Exelixis, Inc.
Via Business Wire
Exelixis Announces CABOMETYX® in Combination with OPDIVO® Provides Efficacy Benefits Regardless of Prior Nephrectomy in Patients with Previously Untreated Advanced Renal Cell Carcinoma Based on CheckMate -9ER Analysis Presented at ESMO 2021
From Exelixis, Inc.
Via Business Wire
Exelixis Statement on the Passing of Two Senior Executives
From Exelixis, Inc.
Via Business Wire
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in September
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Partner Takeda and Ono Receive Approval in Japan for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) for the Treatment of Unresectable or Metastatic Renal Cell Carcinoma
From Exelixis, Inc.
Via Business Wire
Exelixis and Invenra Expand Collaboration to Discover and Develop Novel Biologics in Oncology
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Second Quarter 2021 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Exelixis Announces U.S. FDA Accepts for Priority Review the Supplemental New Drug Application for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
From Exelixis, Inc.
Via Business Wire
Exelixis to Release Second Quarter 2021 Financial Results on Thursday, August 5, 2021
From Exelixis, Inc.
Via Business Wire
Exelixis to Present at the Virtual William Blair Biotech Focus Conference on July 15, 2021
From Exelixis, Inc.
Via Business Wire
Exelixis Chief Medical Officer Gisela M. Schwab, M.D., to Take Medical Leave of Absence
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Evaluate XL092 in Combination with Immuno-oncology Therapies in Advanced Solid Tumors
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Quality-Adjusted Survival Benefit Demonstrated in Analysis of Phase 3 CheckMate -9ER Trial of CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) in Patients with Previously Untreated Advanced Renal Cell Carcinoma
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Consistent Efficacy Benefits Across Subgroups of Phase 3 CheckMate -9ER Trial of CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as a First-line Treatment for Patients with Advanced Renal Cell Carcinoma
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Positive Phase 2 Results for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma at ASCO 2021
From Exelixis, Inc.
Via Business Wire
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in June
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Phase 1b Results from Cohort 6 of COSMIC-021 Trial in Patients with Metastatic Castration-Resistant Prostate Cancer
From Exelixis, Inc.
Via Business Wire
Exelixis Announces First Quarter 2021 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Exelixis Expands its Biotherapeutics Portfolio with Acquisition of GamaMabs Pharma’s First-in-Class Humanized Antibody Program Against a Novel Oncology Target
From Exelixis, Inc.
Via Business Wire
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in May
From Exelixis, Inc.
Via Business Wire
Exelixis to Release First Quarter 2021 Financial Results on Thursday, May 6, 2021
From Exelixis, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.